Arcturus Therapeutics Holdings Inc
ARCT
Company Profile
Business description
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Contact
10285 Science Center Drive
San DiegoCA92121
USAT: +1 858 900-2660
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
176
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,022.40 | 1.20 | -0.01% |
| CAC 40 | 8,120.06 | 8.04 | 0.10% |
| DAX 40 | 24,387.06 | 35.94 | 0.15% |
| Dow JONES (US) | 48,461.93 | 249.04 | -0.51% |
| FTSE 100 | 9,882.21 | 15.68 | 0.16% |
| HKSE | 25,854.60 | 219.37 | 0.86% |
| NASDAQ | 23,474.35 | 118.75 | -0.50% |
| Nikkei 225 | 50,339.48 | 187.44 | -0.37% |
| NZX 50 Index | 13,548.13 | 22.14 | 0.16% |
| S&P 500 | 6,905.74 | 24.20 | -0.35% |
| S&P/ASX 200 | 8,717.10 | 4.10 | -0.05% |
| SSE Composite Index | 3,965.12 | 0.16 | -0.00% |